Submission Details
| 510(k) Number | K170604 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | March 01, 2017 |
| Decision Date | May 30, 2017 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K170604 is an FDA 510(k) clearance for the FilmArray Respiratory Panel 2 (RP2), a Respiratory Virus Panel Nucleic Acid Assay System (Class II — Special Controls, product code OCC), submitted by Biofire Diagnostics, LLC (Salt Lake City, US). The FDA issued a Cleared decision on May 30, 2017, 90 days after receiving the submission on March 1, 2017. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3980.
| 510(k) Number | K170604 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | March 01, 2017 |
| Decision Date | May 30, 2017 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | OCC — Respiratory Virus Panel Nucleic Acid Assay System |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.3980 |
| Definition | A Respiratory Viral Panel Multiplex Nucleic Acid Assay Is A Qualitative In Vitro Diagnostic Device Intended To Simultaneously Detect And Identify Multiple Viral Nucleic Acids Extracted From Human Respiratory Specimens Or Viral Culture. The Detection And Identification Of A Specific Viral Nucleic Acid From Individuals Exhibiting Signs And Symptoms Of Respiratory Infection Aids In The Diagnosis Of Respiratory Viral Infection When Used In Conjunction With Other Clinical And Laboratory Findings. The Device Is Intended For Detection And Identification Of A Combination Of The Following Viruses: Influenza A And Influenza B, Influenza A Subtype H1 And Influenza A Subtype H3, Respiratory Syncytial Virus Subtype A And Respiratory Syncytial Virus Subtype B, Parainfluenza 1, Parainfluenza 2, And Parainfluenza 3 Virus, Human Metapneumovirus, Rhinovirus, And Adenovirus. |